Utility of faecal calprotectin analysis in adult inflammatory bowel disease

Table 1 Correlation of faecal calprotectin with endoscopic findings, histology and clinical indices, when available

Ref.	Patient population	Endoscopic assessment score	Correlation coefficient with endoscopy (r)	Correlation coefficient with histology	Correlation with clinical index (r)
Røseth et al[6]	UC	MAYO	0.57	NA	NA
D'Incà et al[8]	CD	SES-CD	0.48	r = 0.12	NA
D'Incà et al[8]	UC	MAYO	0.51	r = 0.32	NA
Sipponen et al[24]	CD	CDEIS	0.73	NA	0.397(CDAI)
Schoepfer et al[27]	CD	SES-CD	0.75	NA	NA
Jones et al[28]	CD	SES-CD	0.45	NA	0.23 (CDAI)
Sipponen et al[31]	CD	SES-CD	0.64	0.56 (exchange ileal only disease)	0.32 (CDAI)
Sipponen et al[40]	CD	CDEIS	0.83	0.52 (exchange ileal only disease)	NA
Langhorst et al[48]	UC	MAYO	0.49	NA	NA
Langhorst et al[48]	CD	SES-CD	0.35	NA	NA
Hanai et al[63]	UC	Matts	0.81	NA	0.68 (CDAI)
Schoepfer et al[64]	UC	Rachmilewitz	0.83	NA	NA

NA: Not available; MAYO: Mayo score[65]; SES-CD: Simplified endoscopic activity score for Crohn’s disease (CD)[66]; CDEIS: Crohn’s disease endoscopic index of severity[67]; CDAI: Crohn’s disease activity index[68]; Matts: Matts grading[69]; UC: Ulcerative colitis.

Table 2 The use of faecal calprotectin to predict relapse

Author	Patient population	Cut-off calprotectin level	Sensitivity for relapse (%)	Specificity for relapse (%)	Increased risk of relapse
Costa et al[21]	UC	150 μ/L	89	82	14 fold
	CD		87	43	2 fold
D'Incà et al[29]	UC	130 mg/kg	70	70	2.4 fold
	CD		65	62	1.7 fold
García-Sánchez et al[30]	CD + UC	120 μ/g	80	60
	Ileal CD	223 μ/g	83	50
Tibble et al[49]	CD + UC	50 mg/L (250 μ/g)	90	83
Laharie et al[50]	CD post IFX	130 μ/g	61	48
		250 μ/g	43	57
Kallel et al[70]	Colonic CD	340 μ/g	80	90.7	18.8 fold
Gisbert et al[71]	CD + UC	150 μ/g	69	69

UC: Ulcerative colitis; CD: Crohn’s disease; IFX: Infliximab.